Mutual of America Capital Management LLC Has $4.99 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Mutual of America Capital Management LLC decreased its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 3.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 41,997 shares of the company’s stock after selling 1,448 shares during the period. Mutual of America Capital Management LLC’s holdings in Moderna were worth $4,987,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Moderna by 22.6% during the 4th quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock valued at $3,372,058,000 after purchasing an additional 6,248,623 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after buying an additional 1,614,460 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Moderna by 42.9% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock worth $164,724,000 after acquiring an additional 463,960 shares in the last quarter. Matrix Capital Management Company LP acquired a new position in shares of Moderna during the 4th quarter valued at about $45,150,000. Finally, Nikko Asset Management Americas Inc. raised its stake in shares of Moderna by 156.9% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 741,783 shares of the company’s stock valued at $79,044,000 after acquiring an additional 453,004 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Down 3.4 %

MRNA stock opened at $65.69 on Friday. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47. The company has a market cap of $25.18 billion, a PE ratio of -4.19 and a beta of 1.68. The business’s 50-day simple moving average is $90.07 and its 200 day simple moving average is $110.87. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. During the same period last year, the business earned ($3.62) earnings per share. The firm’s revenue for the quarter was down 29.9% compared to the same quarter last year. On average, research analysts anticipate that Moderna, Inc. will post -9.52 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on MRNA shares. Bank of America decreased their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research report on Friday, September 13th. Leerink Partners lowered their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. Jefferies Financial Group lowered shares of Moderna from a “buy” rating to a “hold” rating and cut their target price for the stock from $120.00 to $65.00 in a research report on Friday, September 13th. JPMorgan Chase & Co. downgraded Moderna from a “neutral” rating to an “underweight” rating and lowered their price target for the company from $88.00 to $70.00 in a research report on Friday, September 13th. Finally, Evercore ISI reiterated an “in-line” rating and issued a $120.00 price objective on shares of Moderna in a research note on Thursday, June 27th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $100.44.

Insider Buying and Selling

In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Moderna news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00. Following the sale, the president now directly owns 1,442,089 shares in the company, valued at $174,665,819.68. The disclosure for this sale can be found here. Insiders have sold a total of 93,158 shares of company stock valued at $11,167,312 over the last three months. 15.70% of the stock is owned by corporate insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.